These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38750977)

  • 1. Turning Meters Into Years: Walking to Survive Transthyretin Cardiac Amyloidosis.
    Masri A
    J Am Coll Cardiol; 2024 Jul; 84(1):59-60. PubMed ID: 38750977
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.
    Aimo A; Rapezzi C; Perfetto F; Cappelli F; Palladini G; Obici L; Merlini G; Di Bella G; Serenelli M; Zampieri M; Milani P; Licordari R; Teresi L; Ribarich N; Castiglione V; Quattrone F; De Rosis S; Vergaro G; Panichella G; Emdin M; Passino C
    Eur J Clin Invest; 2021 Nov; 51(11):e13598. PubMed ID: 33982288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis.
    Ioannou A; Fumagalli C; Razvi Y; Porcari A; Rauf MU; Martinez-Naharro A; Venneri L; Moody W; Steeds RP; Petrie A; Whelan C; Wechalekar A; Lachmann H; Hawkins PN; Solomon SD; Gillmore JD; Fontana M
    J Am Coll Cardiol; 2024 Jul; 84(1):43-58. PubMed ID: 38739065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gait abnormalities in older adults with transthyretin cardiac amyloidosis.
    Petros FE; Santos AM; Adeniyi A; Teruya S; De Los Santos J; Maurer MS; Agrawal SK
    Amyloid; 2024 Jun; 31(2):116-123. PubMed ID: 38433466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.
    Orini M; Graham AJ; Martinez-Naharro A; Andrews CM; de Marvao A; Statton B; Cook SA; O'Regan DP; Hawkins PN; Rudy Y; Fontana M; Lambiase PD
    J Am Heart Assoc; 2019 Sep; 8(18):e012097. PubMed ID: 31496332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial Amyloidosis: The Exemplar Interstitial Disease.
    Fontana M; Ćorović A; Scully P; Moon JC
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2345-2356. PubMed ID: 31422120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review.
    Nativi-Nicolau J; Yilmaz A; Dasgupta N; Macey R; Cochrane J; Peatman J; Summers C; Luth J; Zolty R
    J Comp Eff Res; 2024 Jul; 13(7):e230158. PubMed ID: 38869839
    [No Abstract]   [Full Text] [Related]  

  • 11. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
    Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ
    Curr Heart Fail Rep; 2024 Aug; 21(4):344-353. PubMed ID: 38775878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.
    Lointier E; Cariou E; Beneyto M; Fournier P; Lavie-Badie Y; Eyharts D; Bureau C; Lairez O;
    Int J Cardiol; 2024 Dec; 416():132485. PubMed ID: 39187068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.
    Sperry BW; Vranian MN; Tower-Rader A; Hachamovitch R; Hanna M; Brunken R; Phelan D; Cerqueira MD; Jaber WA
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):234-242. PubMed ID: 28917675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis.
    Cuddy SA; Datar Y; Ovsak G; Saith S; Murphy SP; Bay CP; Haddad M; Lilleness B; Muralidhar V; Pipilas A; Vuong J; Guardino E; Maurer MS; Ruberg FL; Falk RH; Dorbala S
    Circ Cardiovasc Imaging; 2022 Nov; 15(11):e014645. PubMed ID: 36378779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
    Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.